FibroBiologics, Inc.
FBLG
$0.5998
-$0.0052-0.86%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.70M | 9.50M | 9.23M | 8.59M | 7.93M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.09M | 14.82M | 13.74M | 12.51M | 11.21M |
| Operating Income | -16.09M | -14.82M | -13.74M | -12.51M | -11.21M |
| Income Before Tax | -13.22M | -7.67M | -11.16M | -17.78M | -19.47M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.22 | -7.67 | -11.16 | -17.78 | -19.47 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.22M | -7.67M | -11.16M | -17.78M | -19.47M |
| EBIT | -16.09M | -14.82M | -13.74M | -12.51M | -11.21M |
| EBITDA | -15.89M | -14.64M | -13.58M | -12.37M | -11.09M |
| EPS Basic | -0.36 | -0.21 | -0.35 | -0.60 | -0.67 |
| Normalized Basic EPS | -0.23 | -0.13 | -0.22 | -0.38 | -0.42 |
| EPS Diluted | -0.36 | -0.21 | -0.35 | -0.60 | -0.67 |
| Normalized Diluted EPS | -0.23 | -0.13 | -0.22 | -0.38 | -0.42 |
| Average Basic Shares Outstanding | 142.95M | 137.04M | 131.50M | 125.60M | 120.31M |
| Average Diluted Shares Outstanding | 142.95M | 137.04M | 131.50M | 125.60M | 120.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |